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MK-801-Increased Glutamatergic and Serotonergic
Transmission in the Medial Prefrontal Cortex of the Rat
Xavier Lo´pez-Gil1, Zoila Babot1, Merce` Amargo´s-Bosch1, Cristina Sun˜ol1, Francesc Artigas1
and Albert Adell*,1
1Department of Neurochemistry and Neuropharmacology, Instituto de Investigaciones Biome´dicas de Barcelona, CSIC (IDIBAPS), Barcelona,
Spain
The administration of noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and ketamine has been
shown to increase the extracellular concentration of glutamate and serotonin (5-HT) in the medial prefrontal cortex (mPFC). In the
present work, we used in vivo microdialysis to examine the effects of the more potent noncompetitive NMDA receptor antagonist, MK-
801, on the efflux of glutamate and 5-HT in the mPFC, and whether the MK-801-induced changes in the cortical efflux of both
transmitters could be blocked by clozapine and haloperidol given systemically or intra-mPFC. The systemic, but not the local
administration of MK-801, induced an increased efflux of 5-HT and glutamate, which suggests that the NMDA receptors responsible for
these effects are located outside the mPFC, possibly in GABAergic neurons that tonically inhibit glutamatergic inputs to the mPFC. The
MK-801-induced increases of extracellular glutamate and 5-HT were dependent on nerve impulse and the activation of mPFC AMPA/
kainate receptors as they were blocked by tetrodotoxin and NBQX, respectively. Clozapine and haloperidol blocked the MK-801-
induced increase in glutamate, whereas only clozapine was able to block the increased efflux of 5-HT. The local effects of clozapine and
haloperidol paralleled those observed after systemic administration, which emphasizes the relevance of the mPFC as a site of action of
these antipsychotic drugs in offsetting the neurochemical effects of MK-801. The ability of clozapine to block excessive cortical 5-HT
efflux elicited by MK-801 might be related to the superior efficacy of this drug in treating negative/cognitive symptoms of schizophrenia.
Neuropsychopharmacology (2007) 32, 2087–2097; doi:10.1038/sj.npp.1301356; published online 14 March 2007
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INTRODUCTION
The acute administration of noncompetitive N-methyl-
D-aspartate (NMDA) receptor antagonists such as phency-
clidine (PCP) and ketamine has been considered as a
pharmacological model of schizophrenia because these
drugs can evoke positive and negative symptoms as well
as characteristic cognitive deficits that closely resemble
those of the illness (Javitt and Zukin, 1991; Krystal et al,
1994; Malhotra et al, 1994; Newcomer et al, 1999). For this
reason, schizophrenia has been associated with NMDA
receptor hypofunction (Javitt and Zukin, 1991; Tamminga,
1998). In rats, PCP and the more potent and selective
noncompetitive NMDA antagonist, dizocilpine (MK-801),
bring about hyperlocomotion and stereotypies (Hertel et al,
1996; Adams and Moghadam, 2001; Homayoun et al, 2004).
These behaviors are thought to result from increased
dopaminergic and serotonergic activities (Giros et al,
1996; Jentsch et al, 1998; Lucki, 1998), and have been
potentially related to positive symptoms of schizophrenia
(Moghaddam and Adams, 1998; Jentsch and Roth, 1999;
Mohn et al, 1999). Furthermore, the behavioral deficits
observed in humans and rodents are distinctly responsive to
clozapine (Bakshi et al, 1994; Maurel-Remy et al, 1995;
Malhotra et al, 1997). Acute NMDA receptor antagonism
has also been reported to increase the release of glutamate
(Moghaddam et al, 1997; Adams and Moghadam, 2001;
Lorrain et al, 2003), dopamine (Moghaddam and Adams,
1998; Mathe´ et al, 1999; Schmidt and Fadayel, 1996), and
serotonin (5-HT) (Martin et al, 1998; Millan et al, 1999;
Adams and Moghadam, 2001; Amargo´s-Bosch et al, 2006) in
the medial prefrontal cortex (mPFC) of rats. These effects
are coincident with an enhanced spontaneous firing rate of
putative pyramidal neurons of the mPFC (Suzuki et al, 2002;
Jackson et al, 2004). The increase in cortical glutamatergic
transmission elicited through the blockade of an excitatory
glutamate receptor (NMDA) may seem contradictory.
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However, it has been postulated that noncompetitive
NMDA receptor antagonists may actually inhibit GABAer-
gic inputs to glutamatergic neurons in the mPFC (Olney and
Farber, 1995; Moghaddam et al, 1997; Krystal et al, 2003). In
fact, GABAergic interneurons in limbic cortex and hippo-
campus are extremely responsive to NMDA receptor
antagonists in comparison with pyramidal neurons (Grunze
et al, 1996; Li et al, 2002), and PCP is able to reduce cortical
GABAergic function (Yonezawa et al, 1998). It remains to be
determined whether this feature can be applied to other
GABAergic cells throughout the brain. Thus, theoretically,
this glutamatergic disinhibition could occur in the mPFC
and/or in areas sending glutamatergic projections to the
mPFC. However, the intra-mPFC administration of PCP or
ketamine was unable to elevate cell firing and loco-
motion (Suzuki et al, 2002) or increase extracellular 5-HT
(Amargo´s-Bosch et al, 2006). Therefore, it appears that
the NMDA receptors responsible for these effects are
located outside the mPFC, possibly in GABA neurons that
would tonically inhibit glutamatergic efferents in areas that
project densely to mPFC, such as hippocampus, thalamus,
or amygdala.
In a previous work, we showed that acute PCP and
ketamine enhanced extracellular 5-HT in the mPFC,
and that this effect was blocked by systemic clozapine and
olanzapine, but not by haloperidol (Amargo´s-Bosch et al,
2006). In the present study, we have tested the hypo-
thesis that MK-801 would also increase serotonergic and
glutamatergic transmission in the mPFC and examined the
effects of clozapine and haloperidol, applied both systemi-
cally and intra-mPFC, on these neurochemical changes.
MATERIALS AND METHODS
Animals
Male Wistar rats (Iffa-Credo, Lyon, France) weighing 250–
280 g were used. They were maintained on a 12 h light/dark
cycle (lights on at 0700) and housed three per cage before
surgery and individually after surgery. Food and water
were always freely available. All experimental procedures
were carried out in strict accordance with European
Communities Council Directive on ‘Protection of Animals
Used in Experimental and Other Scientific Purposes’ of 24
November 1986 (89/609/EEC), and were approved by the
Institutional Animal Care and Use Committees. To reduce
the influence of between-day variations on drug effects,
most experimental groups were not completed at once, but
along the duration of the whole work instead.
Drugs and Reagents
Dizocilpine maleate (MK-801), 2,3-dihydroxy-6-nitro-7-
sulfamoyl-benzo(f)quinoxaline (NBQX), 5-hydroxytrypta-
mine oxalate, o-phthaldialdehyde (OPA) reagent (contain-
ing 1 mg OPA per ml solution with 2-mercaptoethanol as
the sulphydryl moiety), and glutamate were purchased from
Sigma-Aldrich (Tres Cantos, Spain). Clozapine and tetro-
dotoxin (TTX) were from Tocris (Bristol, UK). Haloperidol
was obtained as an injectable solution (5 mg/ml dissolved
in 0.5% lactic acid) from Laboratorios Esteve (Barcelona,
Spain). Citalopram hydrobromide was generously donated
by H Lundbeck A/S (Copenhagen-Valby, Denmark).
MK-801 was dissolved in saline for intraperitoneal (i.p.)
administration or in artificial cerebrospinal fluid (see below
for composition) for local application through dialysis
probes. Clozapine was dissolved in a few drops of glacial
acetic acid and further diluted with saline for subcutaneous
(s.c.) administration, or artificial cerebrospinal fluid for local
application. For s.c. administration, haloperidol (5 mg/ml)
was brought to 1 mg/ml by diluting five times the injectable
solution with saline. When needed, the pH of the final
concentrations was adjusted to 6.5–7.0 with NaHCO3.
Appropriate vehicles were administered in control groups.
Microdialysis Procedures
Concentric dialysis probes with a 4-mm long membrane
were implanted under sodium pentobarbital anesthesia
(60 mg/kg, i.p.) in the mPFC (AP + 3.2 mm, L 0.8 mm, DV
6.0 mm; from bregma), according to Paxinos and
Watson (1986). Microdialysis experiments were conducted
20–24 h after surgery in freely moving rats by continuously
perfusing probes with artificial cerebrospinal fluid contain-
ing 125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl2, 1.18 mM
MgCl2, and 1 mM citalopram. The addition of an uptake
inhibitor to the perfusion fluid is used in some micro-
dialysis studies to decrease clearance from the extracellular
space and magnify the release component of extracellular
5-HT (Adell et al, 2002). On the other hand, low concen-
trations of 5-HT uptake blockers, such as that used in the
present study, are without effect on dialysate glutamate
in vivo (Langman et al, 2006; Queiroz and Artigas,
unpublished results). Interestingly, voltammetric studies
have shown that MK-801 may interact with the serotonin
transporter (Iravani et al, 1999; Callado et al, 2000), thereby
underscoring the importance of including citalopram in the
perfusion fluid.
The artificial cerebrospinal fluid was perfused at a rate of
1.5 ml/min with a WPI model sp220i syringe pump (WPI,
Aston, Stevenage, UK) attached to an overhead liquid swivel
(Instech, Plymouth Meeting, PA). Dialysate samples of 30 ml
were collected every 20 min and divided into two fractions
for the determination of 5-HT (20 ml) and glutamate (10 ml).
The in vitro dialysis probe recoveries for 5-HT and
glutamate were 15 and 17%, respectively. Owing to the
incidental occurrence of chromatographic problems, for
some rats data on only one transmitter (glutamate or 5-HT)
were available. After a 100 min stabilization period, four
dialysate samples were collected to obtain basal transmitter
values (expressed as concentration of transmitter in a
30 ml sample) before any pharmacological treatment. At the
completion of dialysis experiments, rats were given an
overdose of sodium pentobarbital and a fast green solution
was perfused through the dialysis probes to stain the
surrounding tissue for subsequent histological examination.
Biochemical Determinations
The concentration of 5-HT in dialysate samples was
determined by an HPLC system consisting of a Waters
717plus autosampler (Waters Cromatografia, Cerdanyola,
Spain), a Hewlett-Packard series 1050 pump (Agilent
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Technologies, Las Rozas, Spain), a 3-mM octadecylsilica
(ODS) column (7.5 cm 0.46 cm; Beckman, San Ramon,
CA), and an amperometric detector Hewlett-Packard 1049
(Agilent Technologies) set at an oxidation potential of 0.6 V.
The mobile phase consisted of 0.15 M NaH2PO4, 1.8 mM
octyl sodium sulfate, 0.2 mM EDTA (pH 2.8, adjusted
with phosphoric acid), and 30% methanol and was pumped
at 0.7 ml/min (Adell and Artigas, 1998). For the deter-
mination of glutamate, another HPLC system was used,
which consisted of a Waters 717plus autosampler, a Waters
600 quaternary gradient pump, and a Nucleosil 5-mM ODS
column (10 cm 0.4 cm; Teknokroma, Spain). Dialysate
samples were precolumn derivatized with OPA reagent
and all this process was carried out by the autosampler.
Briefly, 90 ml distilled water was added to the 10 ml dialysate
sample and this was followed by the addition of 15 ml of the
OPA reagent. After 2.5 min reaction, 80 ml of this mixture
was injected into the column. Detection was carried out
with a Waters 470 Scanning Fluorescence Detector using
excitation and emission wavelengths of 360 and 450 nm,
respectively. The mobile phase consisted of 0.1 M sodium
acetate, 5.5 mM triethylamine (pH 5.5) containing 10–70%
acetonitrile and was pumped at 0.8 ml/min (Babot et al,
2005). The detection limits for 5-HT and glutamate were
4 fmol and 0.3 pmol, respectively (signal-to-noise ratio 3).
Statistics
Data (mean7SEM) are expressed as fmol/30ml for 5-HT
and pmol/30 ml for glutamate, and shown in figures as
percentages of basal values, averaged from four fractions
collected before treatment. Unless otherwise stated, the
changes in dialysate 5-HT and glutamate were analyzed by
two-way repeated measures analysis of variance (ANOVA)
with time and treatment as factors. When significant effects
were found, post hoc Newman–Keuls multiple comparison
tests were used to compare effects of different treatment
groups. In some cases areas under the curve (AUC) of
selected time intervals were calculated and compared using
ANOVA followed by post hoc Newman–Keuls tests, where
appropriated. The level of significance was set at po0.05.
RESULTS
The basal (predrug) concentrations of 5-HT and gluta-
mate in dialysate samples of the mPFC, not corrected for
in vitro recovery, were 50.371.8 fmol/30 ml (n¼ 155) and
7.270.6 pmol/30 ml (n¼ 164), respectively.
Effects of MK-801
As described previously in the literature (Homayoun et al,
2004; Jackson et al, 2004) the systemic administration of
MK-801 to rats evoked marked hyperlocomotion and
stereotypies (behavioral observation). Two-way ANOVA
showed that with respect to saline-injected group, the
administration of MK-801 (0.5–1 mg/kg, i.p.) enhanced
dose dependently the extracellular concentration of 5-HT
(Figure 1a) as demonstrated by the significant effect of
treatment (F2,20¼ 12.5, po0.0005), time (F15,300¼ 5.9,
po0.00001), and treatment time interaction (F30,300¼
3.3, po0.00001). Post hoc comparisons showed that the
increase elicited by 1 mg/kg MK-801 was higher than that
of 0.5 mg/kg (po0.05; Newman–Keuls test). The systemic
administration of MK-801 also increased extracellular
glutamate (Figure 1b), as shown by the significant effect
of treatment (F2,15¼ 15.0, po0.0003), time (F15,225¼ 5.0,
po0.00001), and treatment time interaction (F30,225¼ 4.6,
po0.00001). However, only the dose of 1.0 mg/kg MK-801
significantly increased dialysate glutamate (po0.001;
Newman–Keuls test). For this reason, this latter dose was
used for subsequent experiments. As described before for
PCP (Adams and Moghadam, 2001), glutamate increased
more slowly than 5-HT after MK-801 administration. On the
contrary, the intra-mPFC perfusion of MK-801 at 30, 100,
and 300 mM for 80 min was without effect on dialysate 5-HT
and glutamate (Figure 1c). To exclude any possible
delayed effect of intracortical MK-801, a further experiment
was carried out in which a concentration of 300 mM of the
compound was perfused through the dialysis probe for 4 h.
This long perfusion of MK-801 did not alter the concentra-
tions of 5-HT and glutamate in the mPFC (Figure 1d).
The local application of the AMPA/kainate antagonist,
NBQX (300 mM), suppressed the MK-801-induced increase
in 5-HT (F1,12¼ 9.2, po0.02; Figure 1a) and glutamate
(F1,10¼ 6.7, po0.03; Figure 1b). When given alone, NBQX
did not change 5-HT and glutamate levels in comparison to
the corresponding control group. TTX (1 mM) also sup-
pressed MK-801-induced increase in 5-HT (F1,12¼ 136.2,
po0.00001; Figure 1a) and glutamate (F1,14¼ 10.0, po0.01;
Figure 1b) although with different efficacy. Thus, whereas
TTX completely abolished the increase in 5-HT elicited by
1 mg/kg MK-801, it reduced glutamate levels to 40% of those
induced by MK-801, as calculated using AUC from time¼ 0
to time¼ 4 h (t¼ 3.1, po0.01; Student’s t-test, two-tailed).
When perfused alone, TTX also abolished basal dialysate
5-HT (F1,10¼ 95.5, po0.00001; Figure 1a), whereas it was
without effect on basal dialysate glutamate (Figure 1b).
Effects of Systemic Administration of
Antipsychotic Drugs
The administration of haloperidol (1 mg/kg, s.c.) failed to
block the increase in 5-HT elicited by MK-801 (Figure 2a),
but effectively blocked that of glutamate (Figure 2b) as
demonstrated by the significant effect of treatment (F3,20¼
12.5, po0.0001), time (F15,300¼ 4.7, po0.00001), and
treatment time interaction (F45,300¼ 3.7, po0.00001). On
the other hand, clozapine (1–5 mg/kg, s.c.) reduced MK-
801-induced increase in dialysate 5-HT in a dose-dependent
manner (Figure 3a), as demonstrated by the significant
effect of treatment (F3,24¼ 7.3, po0.002), time (F15,360¼ 7.3,
po0.00001), and the interaction between both factors
(F45,360¼ 4.2, po0.00001). Clozapine (1–5 mg/kg, s.c.) also
decreased MK-801-induced increase in dialysate glutamate
in a dose-dependent manner (Figure 3b), as demonstrated
by the significant effect of treatment (F3,19¼ 9.4, po0.001),
time (F15,285¼ 8.0, po0.000001), and treatment time
interaction (F45,285¼ 3.2, po0.000001). The effects of
systemic clozapine were significant only at the dose of
5 mg/kg (po0.05 for 5-HT and po0.005 for glutamate;
Newman–Keuls test), although the effect of the lowest dose
almost reached significance for glutamate (p¼ 0.051; New-
man–Keuls test). When administered alone, haloperidol
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(1 mg/kg, s.c.; Figure 2) and clozapine (1–5 mg/kg, s.c.;
Figure 3) failed to alter dialysate 5-HT or glutamate.
Effects of Local Application of Antipsychotic Drugs in
the mPFC
The intra-mPFC perfusion of haloperidol (3, 30 mM) failed
to modify the MK-801-induced increase in dialysate 5-HT
(Figure 4a). However, the same concentrations of haloper-
idol suppressed the MK-801-induced increase in glutamate
in a concentration-dependent manner (Figure 4b), as demo-
nstrated by the significant effect of treatment (F2,19¼ 13.2,
po0.001), time (F15,285¼ 11.0, po0.00001), and the inter-
action between both factors (F30,285¼ 5.5, po0.00001). Post
hoc comparisons showed that only 30 mM haloperidol
significantly blocked the effects of MK-801 on glutamate
(po0.001; Newman–Keuls test). Intra-mPFC perfusion of
clozapine (30, 100, and 300 mM) reduced MK-801-evoked
increase in dialysate 5-HT in a concentration-dependent
manner (Figure 5a), as demonstrated by the significant
effect of treatment (F4,33¼ 7.0, po0.0005), time (F15,495¼
15.9, po0.00001), and treatment time interaction
(F60,495¼ 4.3, po0.00001). Post hoc comparisons showed
that only 300 mM clozapine produced a significant effect
(po0.05; Newman–Keuls test). In contrast, the three
concentrations of clozapine were equipotent in blocking
the MK-801-induced increase in glutamate (Figure 5b),
as demonstrated by the significant effect of treatment
(F4,29¼ 12.7, po0.00001), time (F15,435¼ 7.0, po0.000001),
and their interaction (F60,435¼ 4.9, po0.000001).
When perfused alone, haloperidol (3 and 30 mM) had
no effect on dialysate 5-HT (Figure 6a) and glutamate
(Figure 6b). Intra-mPFC perfusion of clozapine (30, 100,
and 300 mM) decreased dialysate 5-HT in a concentration-
dependent manner (Figure 7a), as demonstrated by the
significant effect of treatment (F3,21¼ 3.7, po0.03), time
(F15,315¼ 2.3, po0.005), and the interaction between
both factors (F45,315¼ 1.6, po0.02). Clozapine had also a
significant effect on dialysate glutamate (Figure 7b), as
demonstrated by the significant effect of treatment (F3,20¼
3.3, po0.05), time (F15,300¼ 2.3, po0.005), and the inter-
action of both factors (F45,300¼ 1.7, po0.01). Post hoc
comparisons showed that only 300 mM clozapine increased
significantly the concentration of glutamate (po0.05;
Newman–Keuls test).
DISCUSSION
The first finding of the present study is that systemic
administration of the NMDA receptor antagonist, MK-801,
Figure 1 Effects of MK-801 (0.5 and 1 mg/kg, i.p.) and of the local perfusion of NBQX (300 mM) and TTX (1mM) on the MK-801 (1 mg/kg, i.p.)-induced
efflux of 5-HT (a) and glutamate (b) in the mPFC. Data (mean7SEM) are expressed as percentage changes of the four basal predrug values. Number of
animals is given in parentheses. NBQX or TTX was perfused from time 0 to time 4 h (line). The effects of the local perfusion for 80 min of three different
concentrations of MK-801 in the mPFC on dialysate 5-HT and glutamate are depicted in (c). Data in (c) are expressed as percentage of AUC calculated from
four consecutive samples of 4 (5-HT) and 5 animals (glutamate). The effects of the local perfusion of 300 mM MK-801 for 4 h in the mPFC on dialysate 5-HT
and glutamate (Glu) are depicted in (d).
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enhanced the extracellular concentration of 5-HT and
glutamate in the mPFC. This was previously shown for
PCP (Adams and Moghadam, 2001). The kinetics of MK-
801-induced changes in glutamate strongly paralleled those
of induction of cortical c-fos mRNA, which also peaked at
3–4 h after the administration of MK-801 (Va¨isa¨nen et al,
1999). This coincidence suggests that induction of c-fos
mRNA synthesis would likely result from increased cortical
glutamate efflux. These increases in 5-HT and glutamate are
dependent on nerve impulse because they were inhibited
by TTX, although to a different extent. Thus, basal and
MK-801-induced elevation of 5-HT were both completely
dependent on nerve impulse. However, basal dialysate
glutamate in the mPFC was not blocked by TTX, in good
agreement with prior work (Moghaddam, 1993; Timmer-
man et al, 1999), which pointed out that only a minor
portion of basal extracellular glutamate is indeed exocyto-
tically released (Timmerman and Westerink, 1997).
Nevertheless, the present study evidenced that MK-801-
stimulated glutamate efflux is largely TTX dependent, that is
released from neurons in an impulse-dependent manner.
This is in line with previous work showing that the efflux of
glutamate elicited by ketamine was also fully dependent on
nerve impulse (Lorrain et al, 2003). It remains to be
determined, however, the provenance of NMDA receptor
antagonist-stimulated extracellular glutamate in the mPFC.
The fact that local perfusion of PCP, ketamine, and MK-801
in the mPFC failed to elicit the increase in glutamate and/or
5-HT (Lorrain et al, 2003; Amargo´s-Bosch et al, 2006, this
study) indicates that the NMDA receptors responsible for
these effects are located outside the mPFC. Our results
are consistent with other data showing that the increased
locomotion and firing or EPSCs of putative pyramidal
neurons of the mPFC following systemic administration of
NMDA receptor antagonists (Suzuki et al, 2002; Jodo
et al, 2003; Jackson et al, 2004) were not mimicked by
intra-mPFC application of these compounds (Aghajanian
and Marek, 2000; Suzuki et al, 2002; Jodo et al, 2005). What
is the actual localization of these NMDA receptors and the
source of the cortical hyperglutamatergic transmission
induced by their blockade? Two of the well-known
ascending glutamatergic inputs to the mPFC arise from
the hippocampus (Carr and Sesack, 1996; De´gene`tais et al,
2003) and the mediodorsal nucleus of the thalamus (Kuroda
et al, 1998), and in both areas glutamatergic neurons are
under the control of GABAergic cells (Gigg et al, 1994;
Figure 2 Effects of pretreatment (first arrow) with haloperidol (1 mg/kg,
s.c.; HAL 1) on the efflux of 5-HT (a) and glutamate (b) in the mPFC
elicited by MK-801 (1 mg/kg, i.p.; second arrow). Data (mean7SEM) are
expressed as percentage changes of the four basal predrug values. Number
of animals is given in parentheses. The control group received two
injections (saline and vehicle) and, for the sake of clarity, is depicted as a
dotted line.
Figure 3 Effects of pretreatment (first arrow) with clozapine (1 or 5 mg/
kg, s.c.; CLZ 1 or CLZ 5) on the efflux of 5-HT (a) and glutamate (b) in the
mPFC elicited by MK-801 (1 mg/kg, i.p.; second arrow). Data (mean7SEM)
are expressed as percentage changes of the four basal predrug values.
Number of animals is given in parentheses. The control group received two
injections (saline and vehicle) and, for the sake of clarity, is depicted as a
dotted line.
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Krimer and Goldman-Rakic, 2001). In accordance with
these findings, it has been shown that the local applica-
tion of PCP into the hippocampus increases locomotion and
the firing of pyramidal neurons of the mPFC in freely
moving rats (Jodo et al, 2005). Furthermore, Sharp and
coworkers have described that the blockade of NMDA
receptors in the anterior thalamus by MK-801 resulted in
injury of cortical pyramidal neurons measured by an
increased synthesis of heat-shock protein 70 (HSP-70) in
limbic cortex (Tomitaka et al, 2000; Sharp et al, 2001). Thus,
all these findings suggest that NMDA receptor antagonists
would attenuate the tonic activation of inhibitory (GABA)
neurons (possibly, though not exclusively, in the hippo-
campus and/or the thalamus), which would result in a
disinhibition of glutamatergic input to the mPFC (Olney
and Farber, 1995; Moghaddam et al, 1997; Krystal et al,
2003). In fact, GABAergic neurons are very sensitive to
NMDA antagonism (Grunze et al, 1996; Li et al, 2002),
and PCP and MK-801 are able to reduce dialysate GABA
in the mPFC (Yonezawa et al, 1998) and striatum (Hondo
et al, 1995). Our results would suggest that the GABAergic
control of glutamate efflux within the mPFC would not
have a tonic nature.
On the other hand, the increased extracellular concentra-
tions of 5-HT and glutamate elicited by MK-801 are
mediated by a stimulation of cortical AMPA receptors
because they were suppressed by intra-mPFC perfusion of
NBQX. Consistent with our findings, it has been shown that
blockade of AMPA/kainate receptors in the prefrontal
cortex inhibited PCP-induced locomotion and stereo-
typy (Takahata and Moghaddam, 2003). Thus, in line with
previous reports (Moghaddam et al, 1997; Adams and
Moghadam, 2001; Lorrain et al, 2003), MK-801 increases
glutamate release onto AMPA/kainate receptors, which, in
turn, elicit an enhanced glutamatergic output from mPFC
neurons, including those projecting to the dorsal raphe
nucleus, thereby increasing serotonergic cell firing and
cortical 5-HT efflux. Although this functional interplay
between the mPFC and the dorsal raphe nucleus is well
documented (Hajo´s et al, 1998; Celada et al, 2001; Martı´n-
Ruiz et al, 2001; Amargo´s-Bosch et al, 2003; Lucas et al,
2005), we presently cannot rule out the possibility of a direct
effect of MK-801 on serotonergic neurons of the dorsal
raphe nucleus (Callado et al, 2000; Tao and Auerbach, 2000)
and its blockade downstream by NBQX acting on AMPA
receptors putatively located in serotonergic terminals
Figure 4 Effects of the intra-mPFC perfusion (line) of haloperidol (3 and
30 mM; HAL 3 and HAL 30, respectively) on the efflux of 5-HT (a) and
glutamate (b) in the mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data
(mean7SEM) are expressed as percentage changes of the four basal
predrug values. Number of animals is given in parentheses. The control
group received an injection of saline and, for the sake of clarity, is depicted
as a dotted line.
Figure 5 Effects of the intra-mPFC perfusion (line) of clozapine (30, 100,
and 300 mM; CLZ 30, CLZ 100, and CLZ 300, respectively) on the efflux of
5-HT (a) and glutamate (b) in the mPFC elicited by MK-801 (1 mg/kg, i.p.;
arrow). Data (mean7SEM) are expressed as percentage changes of the
four basal predrug values. Number of animals is given in parentheses. The
control group received an injection of saline and, for the sake of clarity, is
depicted as a dotted line.
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(Maione et al, 1997). With regard to glutamate, however,
although presynaptic AMPA receptors have been described
in striatal glutamatergic axon terminals (Patel et al, 2001;
Fujiyama et al, 2004), they do not seem to be present in the
cortical counterparts (Fujiyama et al, 2004). Interestingly,
the effect of NBQX on MK-801-induced increase in
5-HT appeared to be biphasic. Thus, NBQX was able to
completely prevent the effect of MK-801 on 5-HT in the first
phase (0–2 h), but not in the second (2–4 h). Although
further research is warranted to know the mechanisms
underlying these effects, it is possible that the late increase
in cortical serotonergic transmission may result from a
direct stimulation of 5-HT cells within the dorsal raphe
nucleus by MK-801 (Callado et al, 2000; Tao and Auerbach,
2000), or from the activation of a different brain circuitry
not including the mPFC (for instance hippocampus -
amygdala - raphe).
Taken together that the effects of MK-801 mostly depends
on glutamatergic projections from regions outside the
mPFC, and that AMPA/kainate receptors are located
predominantly in pyramidal cells, it was expected that
NBQX would have blocked the MK-801-induced increase in
5-HT, but not that of glutamate. Unexpectedly, however,
NBQX was able to block both actions of MK-801. It is
conceivable that MK-801 could have elicited an initial subtle
(not measurable in the present conditions) increase in
glutamate from external sources. This glutamate could have
been able to stimulate pyramidal cells immediately and the
subsequent increase in glutamate measured would have
resulted from a cascade of excitation within pyramidal cells,
instead of directly from an external glutamatergic input.
This proposal is consistent with our finding that a lower
dose of MK-801 (0.5 mg/kg) was able to increase 5-HT
without altering cortical glutamate. Therefore, the present
results imply that the stimulation of cortical AMPA/kainate
receptors can be achieved by subtle changes in glutamate
level, which cannot be detected in the experimental
conditions used because the stimulation of subcortical
glutamatergic afferents immediately leads to the activation
of pyramidal neurons. Overall, our results suggest that
extracellular glutamate measured after MK-801 administra-
tion would partly arise from mPFC or at least depend on
activation of mPFC output.
The second main finding of the present study is that
clozapine and haloperidol differently blocked the MK-801-
induced increase in 5-HT and glutamate. Thus, in line with
our previous work with PCP and ketamine (Amargo´s-Bosch
et al, 2006), the systemic administration of clozapine
suppressed the increase of serotonin in the mPFC, whereas
Figure 6 Effects of the local perfusion of haloperidol (3 and 30mM; HAL
3 and HAL 30, respectively) on the efflux of 5-HT (a) and glutamate (b) in
the mPFC. Data (mean7SEM) are expressed as percentage changes of the
four basal predrug values. Number of animals is given in parentheses.
Figure 7 Effects of the local perfusion of clozapine (30, 100, and 300 mM;
CLZ 30, CLZ 100, and CLZ 300, respectively) on the efflux of 5-HT (a)
and glutamate (b) in the mPFC. Data (mean7SEM) are expressed as
percentage changes of the four basal predrug values. Number of animals is
given in parentheses.
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haloperidol did not. The fact that a higher dose of clozapine
(5 mg/kg) was needed to block the effects of MK-801 in
comparison with those of PCP and ketamine (Amargo´s-
Bosch et al, 2006) could be related to the higher potency of
MK-801 in binding to the NMDA receptor channel. In
contrast, systemic haloperidol completely abolished the
MK-801-induced increase in glutamate. In a previous study,
Adams and Moghadam (2001) showed that clozapine
(10 mg/kg) and haloperidol (0.1 mg/kg) failed to block the
increase in dialysate glutamate elicited by PCP. However, in
this study clozapine was administered i.p., which presum-
ably result in a lower brain concentration of the drug,
possibly insufficient to block the effect of PCP. On the other
hand, it is possible that the blocking actions of clozapine on
glutamate would be more prominent when the stimulated
efflux is higher, which is the case of MK-801 (this study)
compared to PCP (Adams and Moghadam, 2001). In fact,
both clozapine and haloperidol are able to block the effect
of MK-801 on extracellular glutamate. In line with this,
Homayoun and Moghaddam (2007) have recently shown
that clozapine and haloperidol share the ability to markedly
inhibit a small subset of mPFC neurons. Furthermore,
only around 5% of projection neurons in the V layer of the
mPFC project to the dorsal raphe nucleus, according to
Gabbott et al. (2005). Thus, it is conceivable that under
the conditions of the present study (increased 5-HT and
glutamate transmission in the mPFC) haloperidol may be
able to inhibit a subpopulation of pyramidal cells (blockade
of increased glutamate efflux), though sparing cortico-raphe
projections. Alternatively, it could be also possible that
cortico-raphe projecting cells might be inhibited by halo-
peridol, but not to the extent needed to suppress
serotonergic firing distally in the dorsal raphe nucleus and
subsequent cortical 5-HT release. Differences in the
receptor population present in pyramidal cells and the
distinct pharmacological profile of clozapine, acting on
different transmitter receptors particularly abundant in
layer V mPFC neurons, could provide the anatomical
substrate for this differential effect. It thus appears that
serotonergic transmission in the mPFC is regulated by the
concurrent participation of multiple transmitter receptors,
whereas glutamatergic transmission is strongly dependent
on dopamine D2 receptor activation. Further evidence of
the regulation of glutamate release in the mPFC by
dopamine D2 receptors is provided by electrophysiological
studies. Thus, the augmented efflux of dopamine elicited by
the blockade of NMDA receptors (Moghaddam and Adams,
1998; Mathe´ et al, 1999; Schmidt and Fadayel, 1996) may
promote dopamine D2-induced burst firing only in a
small subset of pyramidal cells of the mPFC (Wang and
Goldman-Rakic, 2004), possibly in those cells enriched in
dopamine D2 receptors. In summary, it appears that
dopamine D2 antagonism in the mPFC may be pathway
specific, affecting only a reduced number of pyramidal cells
(Wang and Goldman-Rakic, 2004). In line with our results,
both clozapine and haloperidol inhibit MK-801-induced
induction of cortical c-fos mRNA (Va¨isa¨nen et al, 1999),
which further suggests that this effect may result from
blockade of glutamate efflux. When administered alone,
neither clozapine nor haloperidol, given systemically,
altered the concentrations of 5-HT and glutamate, which
is consistent with previous results (Daly and Moghaddam,
1993; Yamamoto et al, 1994; Cartmell et al, 2001;
Heidbreder et al, 2001). Although recent data from our
lab showed that the dose of 1 mg/kg of both antipsychotics
elicited a maximal reduction of dialysate 5-HT in the mPFC
to B70% of basal values (Amargo´s-Bosch et al, 2006),
such weak effect was comparable to that reported herein
(B80%). The ability of clozapine to attenuate MK-801-
evoked change in cortical 5-HT may be related to its
superior effects in negative/cognitive symptoms. Actually,
clozapine but not haloperidol effectively blocks the
hyperactivity, metabolic activation, neurotoxic cell damage,
as well as the deficits in prepulse inhibition and social
interaction induced by NMDA receptor antagonists
(Corbett et al, 1995; Gleason and Shannon, 1997; Abi-Saab
et al, 1998; Duncan et al, 1998; Olney et al, 1999; Geyer et al,
2001; Farber et al, 2006). Further research is needed to
ascertain the transmitter receptors responsible for such
differences between clozapine and haloperidol.
In good accordance with the effects of systemic admin-
istration, the intra-mPFC perfusion of clozapine was able to
block the increases of both 5-HT and glutamate evoked by
MK-801, whereas haloperidol was only effective in blocking
the increased efflux of glutamate. To the best of our
knowledge, this is the first report that shows the effects of
antipsychotic drugs applied locally into the mPFC on the
neurochemical changes elicited by the systemic adminis-
tration of noncompetitive NMDA receptor antagonists. The
intra-mPFC action of clozapine and haloperidol paralleled
those of their systemic administration, which underscores
the important role of the mPFC in the pharmacological
effects of these antipsychotic drugs. This was not un-
expected given that the prefrontal cortex is involved in goal-
directed actions, such as working memory and cognitive
tasks (Goldman-Rakic, 1995; Ellenbroek et al, 1996; Carli
et al, 2006), and these functions are disrupted after NMDA
receptor antagonism (Abi-Saab et al, 1998; Olney et al, 1999;
Geyer et al, 2001; Jackson et al, 2004) and in schizophrenia
(Weinberger and Gallhofer, 1997; Park et al, 1999). The
mechanisms underlying these differential effects of cloza-
pine and haloperidol remain unknown, but might be the
basis of their differential effectiveness on negative/cognitive
symptoms (Lieberman, 1996). The finding that clozapine
produces opposite effects on glutamatergic transmission
depending on the activity of mPFC neurons is not new. In
fact, clozapine has been shown to increase the activity of
neurons with low baseline firing rates and reduce that of
neurons with higher firing rates (Homayoun and Moghad-
dam, 2007). It is, thus, possible that the local reduction of 5-
HT in the mPFC may be mediated through the action of
clozapine on a multiplicity of receptors, such as dopamine
D1, 5-HT2A, 5-HT2C, a-adrenergic, histamine H1, and/or
muscarinic M1 receptors (Bymaster et al, 1996; Arnt and
Skarsfeldt, 1998). On the other hand, the clozapine-induced
increase in glutamate efflux (albeit only at high concentra-
tion) has been postulated to result from its potentiation
of NMDA transmission through an inhibition of glycine
reuptake and/or a direct agonist action on the glycine
recognition site of NMDA receptors (see Millan, 2005 for
review). Alternatively, extracellular concentration of gluta-
mate may also be secondary to inhibition of GABA efflux
elicited by clozapine (Bourdelais and Deutch, 1994).
Altogether, these findings suggest that abnormally high
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glutamate levels in the mPFC (caused by a primary NMDA
receptor hypofunction) may be related, at least in part, with
some of the psychotic/positive symptoms of schizophrenia
that are generally alleviated by all antipsychotics, probably
through a blockade of dopamine D2 receptors (Coyle
and Tsai, 2004). In contrast, a disruption of 5-HT in the
mPFC could rather be associated to negative symptoms
and/or cognitive impairment, conditions for which cloza-
pine depicts a superior efficacy. Although further research
is needed to verify this hypothesis, it is interesting to note
that some of the atypical antipsychotic drugs (characterized
by their antiserotonergic properties together with a
relatively weaker dopamine D2 antagonism) have been
reported to display a better outcome in the control of
negative symptoms compared with typical antipsychotics
(Meltzer, 1999).
In summary, the results of the present study indicate
that MK-801 (and possibly other noncompetitive NMDA
receptor antagonists) increases the efflux of glutamate and
5-HT in the mPFC through the blockade of NMDA
receptors located outside the mPFC (or at least, outside
the area sampled by dialysis probes), and the activation of
AMPA receptors present in the mPFC. The local effects
of clozapine and haloperidol paralleled those observed after
systemic administration, which emphasizes the relevance
of the mPFC as a site of action of these antipsychotic drugs
in offsetting the neurochemical effects of MK-801. Both
clozapine and haloperidol blocked the effects of MK-801
on cortical glutamate, but only clozapine showed a unique
ability in suppressing an excessive serotonergic activity
in the mPFC. Although this latter action is shared by
olanzapine (Amargo´s-Bosch et al, 2006), further research is
needed to determine whether this is a distinct feature of
atypicality of antipsychotic drugs.
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